Dublin, April 05, 2019 (GLOBE NEWSWIRE) -- The "Global Splenomegaly Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
The splenomegaly therapeutics market will register a CAGR of almost 3% by 2023.
The availability of clinical practice guidelines improves the quality of life of patients, as well as the consistency of care. There are several guidelines and care pathways for the management of splenomegaly, which have been developed by hospitals and professional societies. These are published and practiced with the aim of standardizing disease management in patients with splenomegaly.
For instance, the Hospital for Sick Children has developed a clinical practice guideline for clinicians to provide adequate disease management in children with splenomegaly. In developing countries such as India, the Association of Physicians of India published guidelines for a clinical approach for appropriate diagnosis and management of splenomegaly.
Market Overview
Rising awareness of splenomegaly
The incidence of splenomegaly has been seen along with many primary indications, including infections, autoimmune disorders, and hematological malignancies, which are increasing globally. Hence, the governments of various countries and several non-governmental organizations are striving to increase patient awareness about splenomegaly.
Challenges associated with diagnosis of splenomegaly
Splenomegaly is a nonspecific finding, which is challenging to assess diagnostically, as it is generally a manifestation of an underlying primary disorder. The highly advanced procedures such as point-of-care ultrasonography for the diagnosis for splenomegaly have high sensitivity compared with conventional imaging techniques. However, the poor patient access because of the high cost limits their utilization in diagnosing splenomegaly.
Competitive Landscape
The market appears to be fairly fragmented and with the presence of several vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
- Market segmentation by product
- Comparison by product
- Drug therapy - Market size and forecast 2018-2023
- Vaccination - Market size and forecast 2018-2023
- Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: MARKET SEGMENTATION BY TYPE
- Congestive splenomegaly
- Infiltrative splenomegaly
- Neoplastic splenomegaly
- Immune splenomegaly
PART 10: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Key leading countries
- Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 13: MARKET TRENDS
PART 14: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 15: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- GlaxoSmithKline plc
- Incyte Corporation
- Merck & Co., Inc.
- Novartis AG
- Sanofi
For more information about this report visit https://www.researchandmarkets.com/r/alyp2w
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.